Cartesian Therapeutics (NASDAQ:RNAC – Get Free Report) and Abpro (NASDAQ:ABP – Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, dividends, institutional ownership, risk, profitability, analyst recommendations and earnings.
Volatility & Risk
Cartesian Therapeutics has a beta of 0.38, indicating that its stock price is 62% less volatile than the S&P 500. Comparatively, Abpro has a beta of 0.02, indicating that its stock price is 98% less volatile than the S&P 500.
Insider and Institutional Ownership
87.0% of Cartesian Therapeutics shares are held by institutional investors. Comparatively, 23.3% of Abpro shares are held by institutional investors. 60.3% of Cartesian Therapeutics shares are held by company insiders. Comparatively, 13.7% of Abpro shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cartesian Therapeutics | 1 | 0 | 4 | 0 | 2.60 |
| Abpro | 1 | 1 | 0 | 0 | 1.50 |
Cartesian Therapeutics presently has a consensus price target of $38.50, suggesting a potential upside of 463.69%. Abpro has a consensus price target of $120.00, suggesting a potential upside of 6,117.62%. Given Abpro’s higher possible upside, analysts plainly believe Abpro is more favorable than Cartesian Therapeutics.
Profitability
This table compares Cartesian Therapeutics and Abpro’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cartesian Therapeutics | N/A | N/A | -11.95% |
| Abpro | N/A | N/A | -344.76% |
Earnings & Valuation
This table compares Cartesian Therapeutics and Abpro”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cartesian Therapeutics | $38.91 million | 4.56 | -$77.42 million | ($1.56) | -4.38 |
| Abpro | $180,000.00 | 29.16 | -$7.23 million | ($4.23) | -0.46 |
Abpro has lower revenue, but higher earnings than Cartesian Therapeutics. Cartesian Therapeutics is trading at a lower price-to-earnings ratio than Abpro, indicating that it is currently the more affordable of the two stocks.
Summary
Cartesian Therapeutics beats Abpro on 8 of the 12 factors compared between the two stocks.
About Cartesian Therapeutics
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
About Abpro
Abpro Holdings Inc. is a biotechnology company. The company’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro Holdings Inc., formerly known as Atlantic Coastal Acquisition Corp. II, is based in WOBURN, Mass.
Receive News & Ratings for Cartesian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cartesian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
